The findings of our study demonstrate that risperidone can hinder breast cancer angiogenesis in silico, in vitro and in ovo through its anti-VEGFR2 activity and could serve as a novel repurposed agent for TNBC therapy, warranting further preclinical and clinical studies. Here, KDR is linked to breast cancer.